Ion Beam Applications SA (OTCMKTS:IOBCF – Get Free Report) saw a significant growth in short interest in the month of July. As of July 31st, there was short interest totaling 63,862 shares, a growth of 390.2% from the July 15th total of 13,027 shares. Based on an average trading volume of 319 shares, the days-to-cover ratio is currently 200.2 days.
Ion Beam Applications Stock Performance
Ion Beam Applications stock remained flat at $19.00 during trading hours on Thursday. The company’s stock had a trading volume of 10 shares, compared to its average volume of 861. Ion Beam Applications has a fifty-two week low of $11.45 and a fifty-two week high of $20.10. The business’s 50 day moving average price is $18.95 and its 200-day moving average price is $17.80.
Hedge Funds Weigh In On Ion Beam Applications
Large investors have recently made changes to their positions in the business. Allworth Financial LP bought a new stake in shares of Ion Beam Applications in the 2nd quarter worth approximately $190,000. Simplicity Wealth LLC bought a new position in Ion Beam Applications during the 2nd quarter valued at approximately $205,000. Meeder Advisory Services Inc. bought a new position in Ion Beam Applications during the 2nd quarter valued at approximately $236,000. EP Wealth Advisors LLC purchased a new position in Ion Beam Applications during the second quarter valued at $271,000. Finally, Vise Technologies Inc. purchased a new position in Ion Beam Applications during the second quarter valued at $590,000. 14.86% of the stock is currently owned by hedge funds and other institutional investors.
About Ion Beam Applications
Ion Beam Applications (OTCMKTS: IOBCF) is a Belgium-based medical technology company specializing in the development and deployment of particle therapy solutions for cancer treatment. Founded in 1986 and headquartered in Louvain-la-Neuve, the company is best known for its Proteus® line of proton therapy systems, which are designed to deliver precise, high-energy particle beams that target tumors while sparing healthy tissue. IBA oversees the full project lifecycle, from system design and manufacturing to installation, commissioning, and ongoing service support.
In addition to its flagship proton therapy business, IBA operates a diversified portfolio of technologies for medical and industrial applications.
See Also
- Five stocks we like better than Ion Beam Applications
- Asian Market Circuit Breakers Hit Stocks, Not AI Demand
- Riot Platforms Re-Wires the Ledger for a $9B AI Power Play
- Nebius Just Exploded 34% on Blowout Earnings—Is It Time to Buy?
- Joby’s Defense Pivot Accelerates With $500M Resonant Sciences Deal
Receive News & Ratings for Ion Beam Applications Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ion Beam Applications and related companies with MarketBeat.com's FREE daily email newsletter.
